Clinical Trial

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Study acronym: PANCARDINAL-2
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-02-13; most recent amendment 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2025-04-04
Trial Details
NCT Number NCT06831136
Lead Sponsor The University of Texas Health Science Center, Houston
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 24 participants
Start Date 2025-03-26
Primary Completion 2028-01-20 (estimated)
Study Completion 2030-01-20 (estimated)
Updated on ClinicalTrials.gov 2025-09-10